Inside Biotech · The weekly brief
Always be in the Know.
Breakthrough science, deal flow and regulatory moves — curated weekly by the BioKnow team for the people building biotech and pharma.
Join 21,054 subscribers · One email a week · Unsubscribe anytime
21,054
Newsletter subscribers
Inside Biotech with BioKnow · LinkedIn newsletter
80,233
LinkedIn followers
LinkedIn page analytics · 24 Jun 2026
20.5M
Content impressions, 12 months
15 Jun 2025 – 14 Jun 2026 · LinkedIn content export
What’s inside
Five beats. One five-minute read.
Built for scientists, BD leads, investors and operators.
01 · Deals & Funding
Who is betting on what — and why it matters.
Novo Nordisk · GLP-1 licensing
$3.9B
Takeda × Insilico
$600M
NewLimit
$435M
Superluminal
$60M
Redx Pharma · Series A
$36M
Deal sizes from recent issues · bars √-scaled
02 · Regulatory
FDA, EMA and policy moves — decoded before they hit your pipeline.
SEP 25
FDA CRLs reveal manufacturing pressure
SEP 11
Regulation lags AI-assisted development
AUG 17
FDA flags Aurobindo formulation site
03 · Science
The readouts worth your attention, minus the jargon.
e.g. non-viral in vivo CAR-T
04 · AI × Drug Discovery
Where models meet molecules — partnerships, platforms, proof.
e.g. Merck × Google Cloud · $1B
05 · BioKnow Asks
Original analysis on the questions the industry keeps skipping.
e.g. Are Parkinson’s trials missing the window?
Latest issues
Fresh from the lab.
The archive
Every brief, on the record.
Catch up on the deals, readouts and regulatory calls you missed.
For partners
Be seen by biopharma every day, not just at the booth.
Reach 21,054 subscribers and 80,233 LinkedIn followers across biotech and pharma.
